共 50 条
- [1] Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphomaEXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (09) : 903 - 914Cohen, Jared A.Ghobadi, Armin
- [2] Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic CentersBLOOD, 2024, 144 : 2377 - 2378Sharp, JohnStrati, PaoloBhatta, SubodhHuang, Jennifer J.Thomas, ColinReef, Daniel K.Gorzewski, AlexanderReinert, CatherineTeferra, AndinetPelcovits, AriOllila, ThomasMaakaron, Joseph E.Kamdar, Manali K.Fitzgerald, LindseyKarmali, ReemGrover, NatalieBarta, Stefan K.Voorhees, TimothyShadman, MazyarAhmed, SairahEpperla, Narendranath
- [3] Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)BLOOD, 2024, 144 : 527 - 528Lee, DasomKambhampati, SwethaBobillo, Maria Silvina OdstrcilAdedokun, BabatundeShadman, MazyarOlson, Amanda L.Herrera, Alex F.Lee, Catherine J.Jacobson, Caron A.Bye, MatthewHamadani, MehdiKim, SoyoungDahiya, SaurabhHu, Zhen-HuanSpeth, KellyTo, ChristinaMirjah, Debbie L.Best, TimothyLocke, Frederick L.Ahmed, NausheenTees, Michael T.Pasquini, Marcelo C.Ahmed, Sairah
- [4] FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular LymphomaONCOLOGIST, 2022, 27 (07): : 587 - 594Bouchkouj, NajatZimmerman, MeganKasamon, Yvette L.Wang, CongDai, TianjiaoXu, ZhenzhenWang, XiaofeiTheoret, MarcPurohit-Sheth, TejashriGeorge, Bindu
- [5] A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)BLOOD, 2021, 138Palomba, M. LiaGhione, PaolaPatel, Anik R.Deighton, KevinJacobson, CaronNahas, MyrnaJung, A. ScottHatswell, Anthony J.Kanters, SteveLimbrick-Oldfield, EveWade, Sally W.Snider, Julia ThorntonNeelapu, Sattva S.Riberio, Maria TeresaGribben, JohnRadford, JohnBobillo, SabelaGhesquieres, Herve
- [6] Real-World Patient-Reported Outcomes Among Recipients of Axicabtagene Ciloleucel for Relapsed/Refractory Large B Cell LymphomaBLOOD, 2022, 140 : 5190 - 5191Jim, Heather S. L.Hoogland, Aasha, ILogue, Jennifer M.Aguilar, BrianaLi, XiaoyinSnider, Julia ThorntonWade, Sally WestFu, Christine T.Chavez, Julio C.Jain, Michael D.Lazaryan, AleksandrShah, Bijal D.Locke, Frederick L.
- [7] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and OutcomesBLOOD, 2022, 140 : 4657 - 4660Khurana, ArushiBailey, MegumiIqbal, MadihaBansal, RadhikaLee, Catherine J.Hunter, BradleyLunning, Matthew A.Jaglowski, SamanthaJain, Michael D.Dahiya, SaurabhBachanova, VeronikaFarooq, UmarAhmed, SairahHill, Brian T.Munoz, Javier L.Patel, KrishOluwole, Olalekan O.Lin, Yi
- [8] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68Bell, Jill A.Cherepanov, DashaRevicki, DennisSpeck, Rebecca M.Swett, LauraStumpo, KateRong, YuanxinGordon, Leo I.
- [9] Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Luminari, StefanoHarnett, JamesThieblemont, CatherineProchazka, KatharinaTownsend, WilliamRadford, JohnSerna, AngelJalbert, Jessica J.Kamat, SiddheshWang, JoyAmbati, Srikanth R.Mohamed, HeshamChaudhry, AafiaSanz, HectorHermans, RubenMaissenhaelter, BenediktHampp, ChristianBachy, Emmanuel
- [10] Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature ReviewBLOOD, 2020, 136Kahl, Brad S.Patel, Anik R.Zaidi, OmerSnedecor, Sonya J.Purdum, Anna G.